| Diabetes Mellitus
Rezgovlar vs Tresiba
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Rezvoglar vs Tresiba with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTresiba has a higher rate of injection site reactions vs Rezvoglar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tresiba but not Rezvoglar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rezvoglar
Tresiba
At A Glance
SC injection
Once daily
Long-acting insulin analog
SC injection
Once daily
Long-acting basal insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time every day; use short-acting premeal insulin for the remainder.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily in insulin-naive patients, adjusted based on metabolic needs and blood glucose monitoring results.
Diabetes Mellitus, Type 1 SC once daily; starting dose for insulin-naive adults approximately one-third to one-half of total daily insulin dose with remainder as short-acting insulin divided among meals; when switching, adults start at same unit dose as total daily long/intermediate-acting insulin, pediatric patients (1 year and older) start at 80% of that dose.
Diabetes Mellitus, Type 2 SC once daily; starting dose 10 units for insulin-naive adults; when switching, start at same unit dose as total daily long/intermediate-acting insulin.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine products or any excipient in REZVOGLAR
- Episodes of hypoglycemia
- Hypersensitivity to insulin degludec or any excipient in TRESIBA
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, infection, accidental injury, headache, retinal vascular disorder
Serious Severe hypoglycemia, anaphylaxis, angioedema, bronchospasm, hypotension, shock, hypokalemia, lipodystrophy
Postmarketing Localized cutaneous amyloidosis, medication errors with inadvertent insulin substitution, hyperglycemia or hypoglycemia related to injections into amyloidosis-affected sites
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, headache, sinusitis, gastroenteritis, diarrhea
Serious Hypoglycemia, hypersensitivity reactions (anaphylaxis, angioedema, bronchospasm, hypotension, shock), hypokalemia
Postmarketing Localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia with repeated injections into amyloidosis-affected areas
Pharmacology
Long-acting human insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, lipolysis, and proteolysis while enhancing protein synthesis.
Long-acting basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; TRESIBA forms multi-hexamers after SC injection creating a subcutaneous depot, with protracted action due to delayed absorption from subcutaneous tissue and binding to circulating albumin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rezvoglar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Tresiba
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Rezvoglar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (2/8)
Tresiba
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Rezvoglar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Tresiba
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rezvoglar.
No savings programs available for Tresiba.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RezvoglarView full Rezvoglar profile
TresibaView full Tresiba profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.